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Sir,
We read with interest the phase II results presented by
Kollmannsberger et al (2002b), which recorded no responses to
single-agent irinotecan delivered in a dose of 300–350mg/m
 2
every 3 weeks. This led the authors to conclude that further
evaluation of irinotecan in patients with germ cell cancer could not
be recommended. We note that other recent single-agent phase II
studies in germ cell tumours (oxaliplatin, paclitaxel and gemcitabine
(Sandler et al, 1998; Bokemeyer et al, 1999; Kollmannsberger et al,
2002a)) revealed very low objective response rates (Table 1) The
patients treated in the studies are invariably heterogenous; however,
most have proved refractory to at least two lines of cisplatin-based
therapy and many have received prior high-dose therapy. Since the
number of durable responses following high-dose therapy is of the
region of only 4% and that 86% of patients in Kollmannsberger’s
manuscript had received high-dose therapy, we feel that the results
are not particularly surprising. The median survival in all these
studies is remarkably similar and in the region of 3–6 months.
However, when gemcitabine and paclitaxel were given in combina-
tion, the overall survival was improved (Hinton et al, 2002).
We have recently reported in this journal that there is an
increased level of topoisomerase-1 expression in viable tumour
samples from residual masses postchemotherapy (Berney et al,
2002). Moreover, in vitro studies suggest that the active metabolite
of irinotecan (SN38) may be active in germ cell tumours. Evidence
for this comes from both published data (Ueno et al, 2002) and
currently unpublished work in progress, from our institution.
SN38 appears to have impressive efficacy in both sensitive and
platinum-resistant testicular cancer cell lines (sensitive testicular
lines: IC50¼1.8–7.4nm, resistant testicular line: IC50¼7.0nm). It
is for this reason that we have felt that the investigation of
combination chemotherapy based on irinotecan was warranted.
We have been evaluating a combination chemotherapy regimen
using oxaliplatin 100mg/m
 2 on 1 one, irinotecan 200mg/m
 2 on
day 1 and paclitaxel 80mg/m
 2 on days 1, 8 and 15 (IPO), the
treatment being repeated every 21 days. To date we have treated
nine patients. Two had absolutely refractory disease to cisplatin
and two had relapsed following high-dose chemotherapy. Four
patients have had complete remissions and two have marker
negative partial remissions. Currently, the median survival for this
cohort has not been reached, with a median follow-up of 11
months (range 4–14). Both patients with absolute refractory
disease are currently progression free 11 and 12 months after
treatment.
Table 1 Chemotherapy for relapsed/refractory germ cell tumours
Reference n Treatment
Prior exposure to
platinum (cycles)
Prior high-dose
CT (%)
Refractory/absolute
refractory disease (%)
Response rate
PR/CR (%)
Overall survival
(months)
Kollmannsberger et al 32 Oxaliplatin 7 78 85 13 5
Sandler et al 18 Paclitaxel 46 16 NA 11 3.5
Bokemeyer et al 31 Gemcitabine 7 71 54 19 6
Hinton et al 28 Gemcitabine 463 6 3 6 2 18
Paclitaxel
Bockemeyer et al 15 Irinotecan 6 86 74 0 3
IPO 9 Irinotecan 7 22 22 55 411
Paclitaxel
Oxaliplatin
CT¼chemothotherapy; PR¼partail remission; CR¼complete remission.
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www.bjcancer.comWe conclude that combining drugs with relatively low single-
agent activity, leads to improved results in these patients. This
effect has also been shown when oxaliplatin and irinotecan were
combined in fluorouracil-resistant colorectal carcinoma, as
compared to their single-agent activity (Scheithauer et al, 1999).
Our results are certainly comparable with those of Nomoto et al,
who also used irinotecan in combination with cisplatin in relapsed
disease; however, details regarding platinum sensitivity of their
patients were not given (Nomoto et al, 2002). These in vitro and in
vivo observations lead us to question whether single-agent phase II
studies, conducted in a highly refractory patient population may
best be able to identify potentially useful cytotoxics, and certainly a
negative result must be accepted with some degree of caution.
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Sir,
In their letter, Powles et al disagree with our conclusions drawn
from the results of a phase II study on single-agent irinotecan in
patients with refractory germ cell cancer (Kollmannsberger et al,
2002b). At the same time, they question whether single-agent
phase II studies may be the best way to identify new potentially
active drugs in these patients. This statement is based on
preclinical as well as on preliminary clinical data, which must,
however, be thoroughly discussed.
Preclinical studies demonstrating an increased level of expres-
sion of topoisomerase I in germ cell cancer specimens or an
impressive activity of SN 38, the active metabolite of irinotecan, in
cisplatin-resistant germ cell cancer cell lines, form a strong
rationale for the evaluation of irinotecan in refractory germ cell
cancer patients. However, since we know from many other agents
that an in vitro activity may not always translate into clinical
activity, these preclinical findings do not allow to draw the
conclusion that irinotecan is active in refractory germ cell cancer
patients. Evidence for clinical activity of new agents can only be
provided by prospective clinical trials. Single-agent studies are
typically employed to obtain hints of the potential activity of a new
agent and to form a rationale for potential combinations. Of
course, single-agent studies cannot detect a synergism with other
drugs. Combination regimens in patients with refractory germ cell
cancer may lead to improved results, but these combinations
should include active drugs. Our study investigating irinotecan in
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